FDA Releases Draft Guidance on Estrogen and Hormone Replacement Therapy for Postmenopausal Women

Summary

The Food and Drug Administration (FDA) has made available a draft guidance document outlining recommendations for the clinical evaluation of estrogen and estrogen/progestin drug products used to treat vasomotor symptoms and vulvar and vaginal atrophy in postmenopausal women, replacing its 1995 guidance.